生技药品合约开发市场－2026-2031年预测

预计生技药品合约开发市场将从 2025 年的 82.45 亿美元成长到 2031 年的 127.58 亿美元，复合年增长率为 7.55%。

生技药品合约开发市场是整个医药服务产业中重要且快速成长的细分市场，为包括单株抗体、重组蛋白、细胞和基因疗法以及疫苗在内的复杂生物製药提供外包研发和生产服务。随着生物製剂开发平臺的复杂性和规模不断增长，生物製药公司越来越多地与合约研发生产力机构（CDMO）合作，以利用其专业知识、先进技术和灵活的生产能力。该市场使企业能够缩短研发週期、管理风险并应对生物製药生产过程中固有的技术和监管挑战。

生物疗法研发管线的不断扩展和日益复杂是推动市场成长的根本动力。包括癌症、自体免疫疾病和神经系统疾病在内的慢性病和罕见疾病在全球范围内的日益普遍，持续推动对新型生物治疗方法的需求。然而，开发这些分子需要细胞株开发、上游和下游製程优化、分析表征和製剂科学等方面的高度专业化能力。极少有生物製药公司能够以必要的规模在内部具备所有这些能力，因此，企业对拥有生物製药开发成熟经验的合约研发生产机构（CDMO）的依赖程度持续且不断提高。

生物製药研发固有的技术复杂性和高成本进一步推动了外包的普及。从细胞株到临床供应，生物製药的研发过程涉及复杂的多步骤流程，且每个分子的具体情况都各不特异性。合约研发生产机构（CDMO）在哺乳动物细胞培养、蛋白质纯化和病毒载体生产等领域拥有先进的专业知识，而申办者通常发现从外部获取这些资源更为高效。这种伙伴关係模式使申办方能够将内部资源集中于核心药物发现活动和临床策略，同时减轻了建造和维护先进生物製药设施所需的大量资本投入。

领先的合约研发生产机构 (CDMO) 普遍采用先进且灵活的技术，这已成为一种显着趋势，并推动了客户偏好和市场差异化。一次性生物反应器系统、连续製程、高通量製程开发平台和先进分析技术等创新正逐渐成为标准配备。特别是一次性技术，具有柔软性、交叉污染风险低、宣传活动週期切换快等优势，使其成为拥有多种产品且需求波动较大的合约服务环境的理想选择。投资这些先进平台的 CDMO 可以提供更有效率、扩充性且可客製化的开发解决方案。

从服务领域来看，上游工程开发是关键且高成长的领域。此阶段包括细胞株筛选、培养基优化和生物反应器製程设计，是实现高效价和稳定产品品质的基础。 CDMO（合约研发生产机构）正日益提供高度客製化的上游开发服务，利用平台製程和专有技术来加速这一瓶颈阶段。上游开发能力是关键的差异化因素，因为它直接影响最终生产流程的经济性和扩充性。

从区域来看，北美仍是规模最大、最成熟的市场。这一主导地位得益于该地区生物製药创新企业的高度集中、为生物技术Start-Ups公司提供资金支持的强大创业投资生态系统以及完善的法规结构。该地区蓬勃发展的临床试验和早期研发活动，催生了从药物发现到商业化生产的各类合约服务的强劲需求。此外，北美作为许多全球合约研发生产机构（CDMO）的总部所在地，也进一步巩固了其核心地位。

同时，亚太地区被公认为成长最快的市场。这一增长得益于该地区生物製造基础设施的大规模投资、庞大的初治患者群体（适合开展临床试验）、与西方市场相比更低的运营成本，以及正在与国际标准接轨的不断完善的监管体系。跨国和区域性合约研发生产力机构（CDMO）都在亚太地区拓展业务，以把握这一成长机会，从而为申办方在成本和速度方面提供战略优势。

竞争格局的特点是既有大规模的、提供全方位服务的全球性合约研发生产机构（CDMO），也小规模、专注于特定技术或分子类型（例如细胞疗法、mRNA）的利基型企业。竞争异常激烈，企业之间的差异化体现在技术能力、品质和法规合规记录、计划管理专长以及提供从临床前开发到商业化供应的端到端一体化服务的能力等方面。为了拓展服务范围、取得新技术并扩大地域覆盖，CDMO之间透过策略联盟、併购等方式合作十分普遍。

总之，生技药品合约开发市场正在发展成为全球生物製药产业不可或缺的合作伙伴生态系统。其成长的结构性基础在于药物研发管线持续向复杂生物製剂转型，以及外包专业开发活动的经济与策略合理性。未来市场发展将取决于CDMO（合约研发生产机构）掌握细胞和基因疗法等下一代技术的能力，进一步将数位化和数据驱动方法融入开发流程，并提供灵活且富有韧性的供应链解决方案。成功取决于对卓越科学和营运品质的不懈追求，以及与申办者建立真正的合作伙伴关係，携手走过从生物製剂概念到核准上市这一充满挑战的历程。

本报告的主要优势：

• 深入分析：取得以客户群、政府政策和社会经济因素、消费者偏好、垂直产业和其他细分市场为重点的深入市场洞察，涵盖主要地区和新兴地区。
• 竞争格局：了解主要企业采取的策略倡议，并了解透过正确的策略打入市场的潜力。
• 市场驱动因素与未来趋势：探索动态因素和关键市场趋势，以及它们将如何塑造未来的市场发展。
• 可执行的建议：利用洞察力为策略决策提供讯息，从而在动态环境中开拓新的业务管道和收入来源。
• 受众范围广：对新兴企业、研究机构、顾问公司、中小企业和大型企业都有益处且经济高效。

它是用来做什么的？

产业与市场洞察、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法律规范及其影响、新产品开发、竞争影响

分析范围

• 历史资料（2021-2025 年）和预测资料（2026-2031 年）
• 成长机会、挑战、供应链前景、法规结构、客户行为和趋势分析
• 竞争对手定位、策略和市场占有率分析
• 按业务板块和地区（国家）分類的收入成长和预测分析
• 公司概况（策略、产品、财务资讯、关键趋势等）

目录

第一章执行摘要

第二章市场概述

• 市场概览
• 市场定义
• 分析范围
• 市场区隔

第三章 商业情境

• 市场驱动因素
• 市场限制
• 市场机会
• 波特五力分析
• 产业价值链分析
• 政策和法规
• 策略建议

第四章 技术展望

第五章生技药品合约开发市场（依来源划分）

• 介绍
• 哺乳动物起源
• 非哺乳动物起源

第六章生技药品合约开发市场（按服务划分）

• 介绍
• 上游工程
• 下游工艺
• 其他的

第七章生技药品合约开发市场（依适应症划分）

• 介绍
• 瘤
• 免疫疾病
• 循环系统疾病
• 神经系统疾病
• 其他的

第八章生技药品合约开发市场（按应用领域划分）

• 介绍
• 疫苗
• 基因治疗
• 单株抗体
• 其他的

第九章生技药品合约开发市场（按地区划分）

• 介绍
• 北美洲
  • 我们
  • 加拿大
  • 墨西哥
• 南美洲
  • 巴西
  • 阿根廷
  • 其他的
• 欧洲
  • 德国
  • 法国
  • 英国
  • 西班牙
  • 其他的
• 中东和非洲
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他的
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 印尼
  • 泰国
  • 其他的

第十章 竞争格局与分析

• 主要企业和策略分析
• 市占率分析
• 企业合併、协议、商业合作
• 竞争对手仪錶板

第十一章：公司简介

• WuXi Biologics（WuXi AppTec Co., Ltd）
• Abzena
• FUJIFILM Biotechnologies
• KBI Biopharma Inc.
• AGC Biologics
• Thermo Fisher Scientific Inc.
• Curia Global, Inc.
• Bionova Scientific LLC（Asahi Kasei）
• Boehringer Ingelheim
• Mabion SA
• Lonza Group

第十二章附录

• 货币
• 先决条件
• 基准年和预测年时间表
• 相关人员的主要收益
• 分析方法
• 简称

Biologics Contract Development Market, with a 7.55% CAGR, is expected to grow to USD 12.758 billion in 2031 from USD 8.245 billion in 2025.

The biologics contract development market is a critical and rapidly expanding segment within the broader pharmaceutical services industry, focused on providing outsourced research, development, and manufacturing services for complex biologic drugs. These include monoclonal antibodies, recombinant proteins, cell and gene therapies, and vaccines. As biologic pipelines grow in complexity and volume, biopharmaceutical companies are increasingly partnering with Contract Development and Manufacturing Organizations (CDMOs) to leverage specialized expertise, advanced technologies, and flexible capacity. This market enables innovators to accelerate development timelines, manage risk, and navigate the substantial technical and regulatory challenges inherent in biologic drug creation.

A fundamental driver of market growth is the expanding and increasingly complex pipeline of biologic therapeutics. The rising global prevalence of chronic and rare diseases-including cancers, autoimmune disorders, and neurological conditions-continues to fuel demand for novel biologic treatments. Developing these molecules, however, requires highly specialized capabilities in cell line development, upstream and downstream process optimization, analytical characterization, and formulation science. Few biopharmaceutical companies possess all these capabilities in-house at the scale required, creating a sustained and growing reliance on CDMOs with proven expertise in biologics development.

The intrinsic technical complexity and high cost of biologic development further incentivize outsourcing. The biologics development pathway, from cell line to clinical supply, involves intricate, multi-step processes that are highly molecule-specific. CDMOs offer concentrated knowledge in areas like mammalian cell culture, protein purification, and viral vector production, which is often more efficient for sponsors to access externally. This partnership model allows sponsors to focus internal resources on core discovery and clinical strategy while mitigating the massive capital expenditure required to build and maintain state-of-the-art biologics facilities.

A significant trend is the adoption of advanced and flexible technologies by leading CDMOs, which in turn drives sponsor preference and market differentiation. Innovations such as single-use bioreactor systems, continuous processing, high-throughput process development platforms, and advanced analytics are becoming standard. Single-use technologies, in particular, offer advantages in flexibility, reduced cross-contamination risk, and faster turnaround between campaigns, making them ideal for the multi-product, variable-demand environment of contract services. CDMOs that invest in these advanced platforms can offer more efficient, scalable, and customizable development solutions.

From a service segment perspective, upstream process development represents a critical and high-growth area. This phase, involving cell line selection, media optimization, and bioreactor process design, is foundational to achieving high titers and consistent product quality. CDMOs are increasingly offering highly customized upstream development services, leveraging platform processes and proprietary technologies to accelerate this bottleneck stage. Mastery in upstream development is a key differentiator, as it directly impacts the economic viability and scalability of the eventual manufacturing process.

Geographically, North America remains the largest and most mature market. This dominance is supported by the concentration of major biopharmaceutical innovators, a robust venture capital ecosystem funding biotechnology startups, and a sophisticated regulatory framework. The region sees high volumes of clinical trial activity and early-stage development, creating strong demand for contract services from discovery through to commercial manufacturing. The presence of many global CDMO headquarters also reinforces North America's central role.

Concurrently, the Asia-Pacific region is identified as the fastest-growing market. This growth is propelled by significant investments in regional biomanufacturing infrastructure, a large and treatment-naive patient pool conducive to clinical trials, lower operational costs relative to Western markets, and evolving regulatory systems that are aligning with international standards. Both multinational and regional CDMOs are expanding their footprints in Asia-Pacific to capture this growth, offering sponsors strategic advantages in cost and speed.

The competitive landscape is characterized by a mix of large, full-service global CDMOs and smaller, niche players specializing in specific technologies or molecule types (e.g., cell therapies, mRNA). Competition is intensifying, with differentiation based on technological prowess, quality and regulatory track record, project management expertise, and the ability to offer integrated, end-to-end services from preclinical development through commercial supply. Strategic partnerships, mergers, and acquisitions are common as CDMOs seek to broaden their service portfolios, gain new technologies, and expand geographic reach.

In conclusion, the biologics contract development market is evolving into an indispensable partner ecosystem for the global biopharmaceutical industry. Its growth is structurally supported by the continued shift of the pharmaceutical pipeline toward complex biologics and the economic and strategic logic of outsourcing specialized development work. Future market development will be shaped by the ability of CDMOs to master next-generation modalities like cell and gene therapies, further integrate digital and data-driven approaches into development workflows, and provide resilient and flexible supply chain solutions. Success will depend on a relentless focus on scientific excellence, operational quality, and forming true collaborative partnerships with sponsors to navigate the challenging journey from biologic concept to approved medicine.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2021 to 2025 & forecast data from 2026 to 2031
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information), and Key Developments among others.

Biologics Contract Development Market Segmentation

• By Source
• Mammalian
• Non-Mammalian
• By Service
• Upstream Processing
• Downstream Processing
• Others
• By Indication
• Oncology
• Immunological Disorders
• Cardiovascular Disorders
• Neurological Disorders
• Others
• By Application
• Vaccines
• Gene Therapies
• Monoclonal Antibodies
• Others
• By Geography
• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. BIOLOGICS CONTRACT DEVELOPMENT MARKET BY SOURCE

• 5.1. Introduction
• 5.2. Mammalian
• 5.3. Non-Mammalian

6. BIOLOGICS CONTRACT DEVELOPMENT MARKET BY SERVICE

• 6.1. Introduction
• 6.2. Upstream Processing
• 6.3. Downstream Processing
• 6.4. Others

7. BIOLOGICS CONTRACT DEVELOPMENT MARKET BY INDICATION

• 7.1. Introduction
• 7.2. Oncology
• 7.3. Immunological Disorders
• 7.4. Cardiovascular Disorders
• 7.5. Neurological Disorders
• 7.6. Others

8. BIOLOGICS CONTRACT DEVELOPMENT MARKET BY APPLICATION

• 8.1. Introduction
• 8.2. Vaccines
• 8.3. Gene Therapies
• 8.4. Monoclonal Antibodies
• 8.5. Others

9. BIOLOGICS CONTRACT DEVELOPMENT MARKET BY GEOGRAPHY

• 9.1. Introduction
• 9.2. North America
  • 9.2.1. USA
  • 9.2.2. Canada
  • 9.2.3. Mexico
• 9.3. South America
  • 9.3.1. Brazil
  • 9.3.2. Argentina
  • 9.3.3. Others
• 9.4. Europe
  • 9.4.1. Germany
  • 9.4.2. France
  • 9.4.3. United Kingdom
  • 9.4.4. Spain
  • 9.4.5. Others
• 9.5. Middle East and Africa
  • 9.5.1. Saudi Arabia
  • 9.5.2. UAE
  • 9.5.3. Others
• 9.6. Asia Pacific
  • 9.6.1. China
  • 9.6.2. India
  • 9.6.3. Japan
  • 9.6.4. South Korea
  • 9.6.5. Indonesia
  • 9.6.6. Thailand
  • 9.6.7. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 10.1. Major Players and Strategy Analysis
• 10.2. Market Share Analysis
• 10.3. Mergers, Acquisitions, Agreements, and Collaborations
• 10.4. Competitive Dashboard

11. COMPANY PROFILES

• 11.1. WuXi Biologics (WuXi AppTec Co., Ltd)
• 11.2. Abzena
• 11.3. FUJIFILM Biotechnologies
• 11.4. KBI Biopharma Inc.
• 11.5. AGC Biologics
• 11.6. Thermo Fisher Scientific Inc.
• 11.7. Curia Global, Inc.
• 11.8. Bionova Scientific LLC (Asahi Kasei)
• 11.9. Boehringer Ingelheim
• 11.10. Mabion SA
• 11.11. Lonza Group

12. APPENDIX

• 12.1. Currency
• 12.2. Assumptions
• 12.3. Base and Forecast Years Timeline
• 12.4. Key Benefits for the Stakeholders
• 12.5. Research Methodology
• 12.6. Abbreviations